The Malaysian Reserve

Lilly’s Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk ...
Nature

Blood tests are now approved for Alzheimer’s: how accurate are they?

A second blood test has been been approved by the US Food and Drug Administration to assist in diagnosing Alzheimer’s disease ...
Flow Space on MSN

What Is an APoB Test and Do You Need One for Heart Health?

According to the experts, people who would most benefit from an Apo B test are people: who have metabolic syndrome, diabetes ...

IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.